ClinicalTrials.gg
Status unknownNCT00045968GBMUpdated May 18, 2022

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

A Phase 3 interventional study of Dendritic cell immunotherapy in Glioblastoma Multiforme, Glioblastoma and GBM, sponsored by Northwest Biotherapeutics. Status unknown at 86 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-18.

Sponsored by Northwest Biotherapeutics · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
30th of 1,155
348 · median 33
Started
2006
with 44 others
Phase 3
49 of 1,302
7 open now
Registered
126th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 30th largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 45 that started in 2006, is one of 49 in phase 3, and was the 126th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax-L, with the remaining one third receiving a placebo. All patients will have the option to receive DCVax-L in a crossover arm upon documented disease progression. (note: DCVax-L when used for patients with brain cancer is sometimes also referred to as DCVax-Brain)

Read the detailed description

This Phase III trial is designed to evaluate the impact on survival time, as well as safety, in patients following treatment with DCVax(R)-L, an immunotherapy treatment for GBM. The experimental therapy uses a patient's own tumor lysate and white blood cells from which precursors of the dendritic cells are isolated. The dendritic cell is the starter engine of the immune system. The white cells are then made into dendritic cells and they are educated to "teach" the immune system how to recognize brain cancer cells. Eligible patients will receive a series of injections of DCVax-L, to activate and then boost the immune response to the tumor cells.

The primary study endpoint is OS (overall survival) compared to external controls in newly diagnosed glioblastoma, and the first secondary endpoint is OS compared to external controls in recurrent glioblastoma.

Side effects reported from early trials are mostly mild, and may include skin reactions of redness, pain \& swelling at the injection site.

03

Conditions studied

  • Glioblastoma Multiforme
  • Glioblastoma
  • GBM
  • Grade IV Astrocytoma
  • Glioma
  • Brain Cancer
  • Brain Tumor

Keywords

  • oncology
  • neurology
  • glioma
  • brain tumor
  • brain cancer
  • glioblastoma multiforme
  • glioblastoma
  • newly diagnosed glioblastoma
  • immunotherapy
  • dendritic cells
  • immune therapy
  • GBM
  • Brain cancer, primary
  • tumor vaccine
  • grade IV astrocytoma
  • DCVax
  • Grade IV brain cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

All patients must meet the following inclusion criteria. All tests and eligibility criteria must be completed within four weeks of completion of radiation and chemotherapy, following surgery.

  • Patients must have sufficient tumor lysate protein that was generated from the surgically obtained tumor material. Patients must also have sufficient DCVax-L product available after manufacturing. These determinations will be made by Cognate BioServices, Inc. (Cognate) and communicated to the clinical site through the Sponsor, or its designee.
  • Patients with newly diagnosed, unilateral GBM (Grade IV) are eligible for this protocol. An independent neuropathologist will review this diagnosis during the enrollment process.
  • Subjects ≥18 and ≤70 years of age at surgery who are capable of . Patients must be able to understand and sign the informed consent documents indicating that they are aware of the nature of this study.
  • Patients must have a of >8 weeks.
  • Patients must have a rating of ≥70 at the baseline visit (Visit 3).
  • Primary therapy must consist of surgical resection with the intent for a gross or near total resection of the contrast-enhancing tumor mass, followed by conventional external beam radiation therapy and concurrent Temodar chemotherapy. Patients having a only will be excluded. These primary treatments must be completed at least two weeks prior to first immunization.
  • Patients may have received therapy as part of their primary treatment. Steroid treatment must be stopped at least 10 days prior to leukapheresis.
  • Patients must not have progressive disease at completion of radiation therapy. Patients with suspected pseudoprogression will be enrolled and analyzed separately.
  • Patients must be willing to forego cytotoxic anti-tumor therapies except temozolomide essentially according to the schedule of the Stupp Protocol (Stupp et al. N Engl J Med 352: 987-96, 2005) while being treated with DCVax-L. DCVax-L treatment must be given as described and temozolomide/Temodar treatment schedules must be given essentially according to the Stupp Protocol.
  • Patients must have adequate bone marrow function (e.g., >10 g/dl, white blood count 3600-11,000mm3, absolute granulocyte count ≥1,500/mm3, absolute lymphocyte count ≥1,000/mm3, and count ≥100K/mm3. Eligibility level of hemoglobin can be reached by transfusion.
  • Adequate liver function (, SGOT, and alkaline phosphatase ≤1.5 times upper limits of normals () and total ≤1.5mg/dl), and adequate renal function (BUN or creatinine ≤1.5 times ULN) prior to starting therapy.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
348 participants (estimated)

Study arms

  • Active comparator
    treatment cohort

    Drug: Dendritic cell immunotherapy

  • Placebo comparator
    Placebo Chohort

    Autologous PBMC

    Drug: Dendritic cell immunotherapy

Interventions

  • Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.

    Also known as: DCVax-L, DCVax, DCVax-Brain

06

What researchers measure

Primary outcomes

  1. The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in newly diagnosed glioblastoma.

    Time frame: Until death

Secondary outcomes

  1. The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in recurrent GBM.

    Time frame: Until death

07

Study locations

86 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Sutter East Bay Neuroscience Institute-Eden Medical Center
    Castro Valley, California 94546, United States
  • City of Hope
    Duarte, California 91010, United States
  • UCSD Moores Cancer Center
    La Jolla, California 93093, United States
  • Kaiser Permanente - Los Angeles
    Los Angeles, California 90027, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • St. Joseph Hospital of Orange
    Orange, California 92868, United States
  • University of California, Irvine Medical Center
    Orange, California 92868, United States
  • Kaiser Permanente - Redwood City
    Redwood City, California 94063, United States
  • Sutter Institute for Medical Research
    Sacramento, California 95816, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Colorado Neurological Institute
    Englewood, Colorado 80113, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20057, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
  • Mount Sinai Community Clinical Oncology Program
    Miami Beach, Florida 33140, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
  • Cadence Cancer Center
    Warrenville, Illinois 60555, United States
  • IU Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Markey Cancer Center/University of Kentucky
    Lexington, Kentucky 40536, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Michigan Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Spectrum Health
    Grand Rapids, Michigan 49503, United States
  • John Nasseff Neuroscience Institute at Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • St. Luke's Hospital
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • The Brain Tumor Center at JFK Medical Center
    Edison, New Jersey 08818, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • The Valley Hospital
    Ridgewood, New Jersey 07450, United States
  • Overlook Hospital
    Summit, New Jersey 07902, United States
  • Capital Health Regional Medical Center
    Trenton, New Jersey 08638, United States
  • Long Island Brain Tumor Center at Neurological Surgery, P.C.
    Lake Success, New York 11042, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • New York University Clinical Cancer Center
    New York, New York 10016, United States
  • Mount Sinai Medical Center
    New York, New York 10029-6574, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Stony Brook Medicine
    Stony Brook, New York 11794, United States
  • Brain and Spine Surgeons of New York and Northern Westchester Hospital
    White Plains, New York 10604, United States
  • University of North Carolina, Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati Cancer Institute
    Cincinnati, Ohio 45267, United States
  • University Hospitals Seidman Cancer Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • OhioHealth
    Columbus, Ohio 43214, United States
  • Oklahoma University Health Science Center
    Oklahoma City, Oklahoma 73104, United States
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Jefferson Hospital for Neuroscience
    Philadelphia, Pennsylvania 19107, United States
  • Temple University School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Medical University of South Carolina Hospitals and Clinics
    Charleston, South Carolina 29425, United States
  • Saint Thomas Research Institute
    Nashville, Tennessee 37205, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232, United States
  • Baylor Research Institute
    Dallas, Texas 75246, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Cancer Therapy & Research at University of Texas Health Science Center San Antonio
    San Antonio, Texas 78229, United States
  • Benaroya Research Institute at Virginia Mason
    Seattle, Washington 98101, United States
  • Swedish Hospital Neuroscience Research
    Seattle, Washington 98122, United States
  • Aurora Saint Luke's Medical Center
    Milwaukee, Wisconsin 23215, United States
  • Montreal Neurological Institute, McGill University
    Montreal, Quebec H3A 2B4, Canada
  • CHUS - Hôpital Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • Universitätsklinikum Heidelberg Neurochirurgische Klinik
    Heidelberg, Baden-Württemberg 69120, Germany
  • Katharinenhospital
    Stuttgart, Baden-Württemberg 70174, Germany
  • Universitätsklinikum FrankfurtKlinik und Poliklinik für Neurochirurgie
    Frankfurt, Hesse 60528, Germany
  • Universitätsklinikum Bonn Nervenklinik (Zentrum), Klinik und Poliklinik für Neurochirurgie
    Bonn, North Rhine-Westphalia 53105, Germany
  • Universitätsklinikum Klinik für allgemeine Neurochirurgie
    Köln, North Rhine-Westphalia 50924, Germany
  • BG-Kliniken Bergmannstrost, Klinik für Neurochirurgie
    Halle, Saxony-Anhalt 06112, Germany
  • Klinik für Neurochirurgie, Klinikum Chemnitz gGmbH
    Chemnitz, Saxony 09116, Germany
  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
    Dresden, Saxony 01307, Germany
  • Neurochirurgische Klinik
    Hamburg, 20246, Germany
  • Addenbrookes NHS Trust
    Cambridge, Cambridgeshire, East Anglia CB2 2QQ, United Kingdom
  • Kings College Hosital NHS Foundation Trust
    London, Greater London SE5 9RS, United Kingdom
  • University College Hospital London
    London, Greater London WC1E 6BT, United Kingdom
  • University Hospital of Birmingham NHS Foundation Trust
    Birmingham, West Midlands N15 2WB, United Kingdom
08

References and documents

Publications

  • Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023 Jan 1;9(1):112-121. doi: 10.1001/jamaoncol.2022.5370. PubMed 36394838 ↗
  • Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum In: J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1. PubMed 29843811 ↗
  • Badhiwala J, Decker WK, Berens ME, Bhardwaj RD. Clinical trials in cellular immunotherapy for brain/CNS tumors. Expert Rev Neurother. 2013 Apr;13(4):405-24. doi: 10.1586/ern.13.23. PubMed 23545055 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006 and a primary completion of Nov 2022. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2002
First posted
Sep 19, 2002
Start
Dec 2006
Primary completionEst.
Nov 2022
Last update
May 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00045968
Lead sponsor
Northwest Biotherapeutics
Responsible party
Sponsor
First posted
Sep 19, 2002
Start date
Dec 2006
Primary completion
Nov 2022 (estimated)
Last update
May 18, 2022

Study contacts

Linda Liau, M.D.
principal investigator · University of California, Los Angeles
Marnix L. Bosch, MBA, PhD
study director · Northwest Biotherapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dendritic Cell

Start the discussion